Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cogent

52.06
+0.91001.78%
Post-market: 52.060.00000.00%16:19 EDT
Volume:513.02K
Turnover:26.77M
Market Cap:2.57B
PE:-12.15
High:52.83
Open:52.14
Low:51.87
Close:51.15
Loading ...

Stock Track | Cogent Communications Stock Plummets on Disappointing Q3 Results

Stock Track
·
07 Nov 2024

Cogent Communications Holdings Inc reports results for the quarter ended in September 30 - Earnings Summary

Reuters
·
07 Nov 2024

Cogent Communications Q3 Net Loss Widens as Revenue Falls; Quarterly Dividend Boosted

MT Newswires Live
·
07 Nov 2024

BRIEF-Cogent Communications Reports Q3 2024 Results And Increases Its Regular Quarterly Dividend On Its Common Stock

Reuters
·
07 Nov 2024

Cogent Communications (CCOI) Reports Q3 Loss, Misses Revenue Estimates

Zacks
·
07 Nov 2024

Cogent: Q3 Earnings Snapshot

Associated Press Finance
·
07 Nov 2024

Cogent Comms Hldgs Q3 Sales $260.40M Beat $258.69M Estimate

Benzinga
·
07 Nov 2024

BRIEF-Cogent Communications Q3 Basic EPS USD -1.33

Reuters
·
07 Nov 2024

Cogent Communications Q3 Gross Profit USD 9.835 Million

THOMSON REUTERS
·
07 Nov 2024

Cogent Communications Q3 EBIT USD -57.829 Million

THOMSON REUTERS
·
07 Nov 2024

Cogent Communications Q3 Adjusted Gross Margin 37.4%

THOMSON REUTERS
·
07 Nov 2024

Cogent Communications Reports Third Quarter 2024 Results and Increases Its Regular Quarterly Dividend on Its Common Stock

THOMSON REUTERS
·
07 Nov 2024

Cogent Communications Holdings Inc - Increases Quarterly Dividend to $0.995 per Share

THOMSON REUTERS
·
07 Nov 2024

Cogent Communications Holdings Inc expected to post a loss of $1.19 a share - Earnings Preview

Reuters
·
06 Nov 2024

Buy Recommendation for Cogent Biosciences Amid Unjustified Stock Decline

TIPRANKS
·
06 Nov 2024

Cogent selloff on ‘old news’ is ‘unwarranted,’ says Citi

TIPRANKS
·
06 Nov 2024

Promising Developments and Financial Stability Propel Cogent Biosciences to a Buy Rating

TIPRANKS
·
06 Nov 2024

Cogent data has positive read-through to Blueprint, says Barclays

TIPRANKS
·
06 Nov 2024

Mixed Efficacy and Safety Profiles Lead to Hold Rating for Blueprint Medicines and Cogent Biosciences

TIPRANKS
·
06 Nov 2024

Cogent Biosciences down after bezuclastinib abstract released

TIPRANKS
·
06 Nov 2024